Tradestie Institutional Equity Comparison Engine
NVS vs BMY โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BMY Overall Edge
BMY Captures Institutional Edge (4โ0 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Bristol-Myers Squibb Co. (BMY) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, NVS trades at 16.2x Forward P/E with 34.0% operating margin (+4.7% YoY revenue) versus BMY at 9.5x Forward P/E and 32.4% operating margin (+6.9% YoY). In options structure, NVS sits in UNCLASSIFIED (6th %ile IV; Dealer Gamma Walls on Pro) against BMY sits in CONSOLIDATION (56th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
BMY
NVS 16.2x vs BMY 9.5x Fwd P/E
Growth & Margin Winner
BMY
Op Margin 34.0% vs 32.4% ยท YoY +4.7% vs +6.9%
Momentum & Technical Winner
BMY
1Y +22.5% vs +30.2% ยท 52W Pos 81% vs 77%
Options & Structure Winner
BMY
UNCLASSIFIED (6th %ile IV) vs CONSOLIDATION (56th %ile IV)
NVS
NYSE
Novartis AG
Pharmaceutical Preparations
$161.59
+0.68% 1D
Market Cap
$302.9B
1M Return
+7.28%
1Y Return
+22.5%
Forward P/E
16.2x
Unified AI Score
41.5 / 100
SELL
Tech 29.0
Fund 38.0
Flow 50.0
Mom 21.1
BMY
NYSE
Bristol-Myers Squibb Co.
Pharmaceutical Preparations
$63.30
-0.21% 1D
Market Cap
$127.4B
1M Return
+5.93%
1Y Return
+30.16%
Forward P/E
9.5x
Unified AI Score
57.3 / 100
HOLD
Tech 62.0
Fund 61.0
Flow 70.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
NVS +22.5%
BMY +30.16%
Spread: +7.66 pp (BMY Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
NVS TTM Op. Margin: 34.0%
BMY TTM Op. Margin: 32.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs BMY. Trailing 12-month operating profitability (NVS 34.0% vs BMY 32.4%) and valuation multiples (NVS 16.2x vs BMY 9.5x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NVS | BMY | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $302.9B | $127.4B | Larger Scale | NVS |
| Trailing P/E Ratio Valuation | 30.6x | 13.8x | Lower Multiple | BMY |
| Forward P/E Ratio Valuation | 16.2x | 9.5x | Lower Multiple | BMY |
| Revenue Growth (YoY) Growth | +4.7% | +6.9% | Higher Growth | BMY |
| Operating Margin (TTM) Profitability | 34.0% | 32.4% | Higher Margin | NVS |
| Net Profit Margin Profitability | 17.5% | 18.5% | Higher Margin | BMY |
| Return on Equity (ROE) Capital Efficiency | 24.3% | 44.0% | Higher ROE | BMY |
| 52-Week Range Position Momentum | 81% ($123โ$170) | 77% ($45โ$69) | Stronger Trend | NVS |
| Beta / 30D Volatility Risk Regime | 0.31ฮฒ ยท 27% Vol | 0.17ฮฒ ยท 31% Vol | Lower Realized Risk | NVS |
| Unified Institutional Score Composite Signal | 41.5 / 100 (SELL) | 57.3 / 100 (HOLD) | Higher Composite | BMY |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full NVS vs BMY Buy Guide
NVS
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
6th %ile
IV Regime
Compressed (<25th %ile)
BMY
CONSOLIDATION
50d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
56th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither NVS nor BMY registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.